156 filings
Page 6 of 8
8-K
ay7 9kk6l
5 Jun 18
Akcea Therapeutics Appoints Industry Leader
4:30pm
8-K
8yn21us5
3 May 18
Akcea Reports Financial Results and Highlights for First Quarter 2018
4:15pm
DEF 14C
3dbh21so
20 Apr 18
Information statement
12:00am
8-K
zi7qddf3pya2
20 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
78jflz61ltqxjkgq
17 Apr 18
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
12:00am
8-K
3yixrv5
6 Apr 18
Entry into a Material Definitive Agreement
12:00am
DEFA14A
v6vuj3u4jy82j
28 Mar 18
Additional proxy soliciting materials
12:00am
8-K
phuhmcc m93xzzg7mrcc
26 Mar 18
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
12:00am
DEF 14A
izdwv5
26 Mar 18
Definitive proxy
12:00am
DEFA14A
r94iwpd4 8ui6
26 Mar 18
Additional proxy soliciting materials
12:00am
DEFA14A
9vk1 ln1cs7gu5f
16 Mar 18
Additional proxy soliciting materials
12:00am
8-K
y8dpllk7
16 Mar 18
Important Information for Investors and Security Holders
12:00am
PRE 14A
7zjfbwf8ttdydiv
15 Mar 18
Preliminary proxy
12:00am
DEFA14A
23whco0pzulv1lrs724
15 Mar 18
Additional proxy soliciting materials
12:00am
8-K
ixmpbglrm k2
15 Mar 18
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
12:00am
10-K
md32gluusn9xf363ilhm
28 Feb 18
Annual report
12:00am
8-K
jjbthxpzohb2pmxcvmxd
27 Feb 18
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017
12:00am
8-K
murjrn8
30 Nov 17
Entry into a Material Definitive Agreement
12:00am